Abstract
Rodent Oatp2 is a hepatic uptake transporter for such compounds as cardiac glycosides. In the present study, we found that fasting resulted in a 2-fold induction of Oatp2 expression in liver of mice. Because the cAMP-protein kinase A (PKA) signaling pathway is activated during fasting, the role of this pathway in Oatp2 induction during fasting was examined. In Hepa-1c1c7 cells, adenylyl cyclase activator forskolin as well as two cellular membrane-permeable cAMP analogs, dibutyryl cAMP and 8-bromo-cAMP, induced Oatp2 mRNA expression in a time- and dose-dependent manner. These three chemicals induced reporter gene activity in cells transfected with a luciferase reporter gene construct containing a 7.6-kilobase (kb) 5′-flanking region of mouse Oatp2. Transient transfection of cells with 5′-deletion constructs derived from the 7.6-kb Oatp2 promoter reporter gene construct, as well as 7.6-kb constructs in which a consensus cAMP response element (CRE) half-site CGTCA (–1808/–1804 bp) was mutated or deleted, confirms that this CRE site was required for the induction of luciferase activity by forskolin. Luciferase activity driven by the Oatp2 promoter containing this CRE site was induced in cells cotransfected with a plasmid encoding the protein kinase A catalytic subunit. Cotransfection of cells with a plasmid encoding the dominant-negative CRE binding protein (CREB) completely abolished the inducibility of the reporter gene activity by forskolin. In conclusion, induction of Oatp2 expression in liver of fasted mice may be caused by activation of the cAMP-dependent signaling pathway, with the CRE site (–1808/–1804) and CREB being the cis- and trans-acting factors mediating the induction, respectively.
Footnotes
-
This work was funded by grant ES09649 from the National Institutes of Health.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.106.030841.
-
ABBREVIATIONS: OATP/Oatp, human/nonhuman organic anion transporting polypeptide; CAR, constitutive androstane receptor; PKA, protein kinase A; CREB, cAMP response element binding protein; CRE, cAMP response element; dbcAMP, di-butyryl cAMP; 8-Br-cAMP, 8-bromo cAMP; PPAR, peroxisome proliferator-activated receptor; PCR, polymerase chain reaction; bp, base pair(s); Gapdh, glyceraldehyde-3-phosphate dehydrogenase; kb, kilobase(s); ACREB, dominant-negative CREB; DPM 904, 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine.
- Received September 12, 2006.
- Accepted January 22, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|